Latin America's Pharma-Bio Industry Faces Delays in Investment Approvals, an Industrial Info Market Brief
Latin America's Pharma-Bio Industry Faces Delays in Investment Approvals, an Industrial Info Market Brief
Attachment: LA COVID 0620
Companies in Latin America's Pharmaceutical & Biotech Industry have delayed the authorizations for expenditure on 93 capital-spending projects, with a total investment value of more than $245 million, during the second quarter of 2020. This period has seen a tightening of lockdowns and restrictions related to the COVID-19 pandemic.
Subscribe Now!(All Fields Required)
Related Articles
Articles related to this company
- France Plans $55 Billion in Windfarms as Offshore Projects Gain Momentum
- Africa's Fertilizer Demand Sparks $5.8 Billion of Projects
- Poland's PGE Plans $7 Billion Renewable Energy Push
- Peru's Runoff Presidential Election Could Impact $45 Billion in Mining Proj...
- Industrial Construction Activity Up 37% So Far in 2021
Quick Links
- Home
- About Us
- Contact Us
- For Traders
Global Market Intelligence
- GMI Database Platform
- GMI Platform Tools
- Industry Coverage
- Analytics & Insights
- Advertising
